ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 57

Repository Corticotropin Injection (H.P. Acthar® Gel) Inhibits Bone Degradation in Rat Adjuvant-Induced Arthritis Model

Dale Wright, Ben Zweifel, Steve Settle and Rick Fitch, Pharmacology, Mallinckrodt Pharmaceuticals, Hazelwood, MO

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: adjuvant arthritis and osteoclasts, Bone

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Rheumatoid Arthritis – Animal Models Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Repository corticotropin injection (RCI: H.P. Acthar® gel) contains a purified porcine pituitary ACTH-analogue, and is an FDA-approved treatment for short-term adjunctive therapy of acute episode or exacerbation in rheumatic disorders.  It has been suggested that ACTH modulates the immune response via binding to melanocortin receptors (MC1R to MC5R).  These receptors are expressed on a number of cells including immune cells and bone cells, and have been shown to modulate several immune responses. This study was designed to investigate the effects of RCI treatment compared to prednisolone with regard to arthritis disease attenuation and bone protection.

 

Methods:

Rat adjuvant-induced arthritis (AIA) model was used to determine efficacy in the subacute inflammation setting. Disease was induced by an injection of a lipoidal amine in Freund’s complete adjuvant (FCA) on day 0. The AIA rats were treated with either vehicle, prednisolone (5 mg/kg) or RCI (40, 160, 400 IU/kg) every other day by subcutaneous injection beginning on the day of disease induction and continuing for 15 days (8 total doses). Disease progression was monitored on days 7-14 by measuring both paw diameter and body weight. Inflammation and bone damage were evaluated histologically at the end of the study.

Results:

Treatment with RCI showed significant and dose responsive inhibition of disease induction as determined by evaluation of ankle diameter (area under the curve (AUC) inhibition of 44%, 74%, 94% for 40 IU/kg, 160 IU/kg and 400 IU/kg, respectively) whereas prednisolone reduced swelling by 33%.  Microscopic examination of the ankle joints showed that RCI significantly inhibited total histopathology sum score by 64% and 85% at 160 IU/kg and 400 IU/kg, respectively, while treatment with prednisolone resulted in 33% inhibition, which was not significantly different from the controls.  Furthermore, RCI inhibited inflammation-related bone resorption and reduced the number of osteoclasts in the inflamed joint.  Interestingly, prednisolone significantly reduced the number of osteoclasts but did not show a significant benefit on joint damage as evaluated by bone resorption and cartilage damage.

Conclusion:

RCI treatment significantly inhibited the development of disease in rat AIA, whereas prednisolone treatment alone only showed a minor benefit.  Furthermore, there was a significant reduction in the number of osteoclasts following RCI treatment.  These findings support the use of RCI for treatment of rheumatoid arthritis and suggest a potential bone sparing effect.

 

Histopathology Scoring

 

Treatment

Inflammation

Pannus

Cartilage Damage

Bone Resorption

Periosteal Bone Formation

Osteoclast Numbers

Disease

5.56 ± 0.11

0.97 ± 0.16

0.97 ± 0.16

4.81 ± 0.09

1.03 ± 0.24

14.04 ± 0.95

RCI 40 IU/kg

4.13 ± 0.38

0.66 ± 0.08

0.66 ± 0.08

2.50 ± 0.52*

0.69 ± 0.22

6.75 ± 0.84*

RCI 160 IU/kg

2.56 ± 0.24*

0.34 ± 0.08*

0.44 ± 0.06*

1.22 ± 0.29*

0.19 ± 0.06*

2.82 ± 0.58*

RCI 400 IU/kg

1.41 ± 0.13*

0.03 ± 0.03*

0.06 ± 0.04*

0.44 ± 0.26*

0 ± 0*

0.70 ± 0.34*

Prednisolone

4.06 ± 0.32

0.59 ± 0.08

0.59 ± 0.08

3.28 ± 0.23

0.38 ± 0.05*

8.67 ± 0.93*

Severity Score = 0-7, Mean ± SE

Osteoclast Count (in 5 different joint areas of potential disease related bone resorption)

* p<0.01 Dunn’s multiple comparisons test

 

 

 


Disclosure: D. Wright, Mallinckrodt Pharmaceuticals, 1, 3; B. Zweifel, Mallinckrodt Pharmaceuticals, 3; S. Settle, Mallinckrodt Pharmaceuticals, 1, 3; R. Fitch, Mallinckrodt Pharmaceuticals, 1, 3.

To cite this abstract in AMA style:

Wright D, Zweifel B, Settle S, Fitch R. Repository Corticotropin Injection (H.P. Acthar® Gel) Inhibits Bone Degradation in Rat Adjuvant-Induced Arthritis Model [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/repository-corticotropin-injection-h-p-acthar-gel-inhibits-bone-degradation-in-rat-adjuvant-induced-arthritis-model/. Accessed May 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/repository-corticotropin-injection-h-p-acthar-gel-inhibits-bone-degradation-in-rat-adjuvant-induced-arthritis-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences